Bacterial Nanocellulose as a Platform for Three‐Dimensional Colon Cancer Cultures: Physicochemical Characterization and Biocompatibility Evaluation
Macromolecular Bioscience · 2026
DOI: 10.1002/mabi.70272 ↗Kurz gefasst
Fachartikel in der Zeitschrift Macromolecular Bioscience, 2026. Verfasst von M Londoño und 5 weiteren Autor:innen. Beteiligte Einrichtung: Systems Biology Research Group, School of Health Sciences, Faculty of Medicine, Universidad Pontificia Bolivariana, Medellín, Colombia. Hauptthemen laut MEDLINE: Cellulose, Colonic Neoplasms, Biocompatible Materials, Tissue Scaffolds. Die Arbeit nennt 62 Literaturangaben. Gefördert von: Ministerio de Ciencia, Tecnología e Innovación, Projects Nanovehiculos, Preclínico.
Abstract (Originalsprache)
3D in vitro cancer models provide a more physiologically relevant representation of tumor architecture and cell–matrix interactions than conventional monolayer cultures. This study evaluated bacterial nanocellulose (BNC) as a scaffold for the 3D culture of colorectal cancer cells. BNC scaffolds were produced using paraffin spheres as porogens and subsequently characterized in terms of morphology, chemical structure, thermal stability, and mechanical properties. Human colorectal cancer cell lines SW480 and SW620, along with CHO‐K1 cells, were exposed to BNC leachates and cultured on 2D and 3D BNC matrices. Cells grown on 2D BNC exhibited typical monolayer proliferation, whereas 3D matrices allowed cell infiltration and volumetric distribution, supporting multicellular organization and the formation of spheroid‐like aggregates. Cell viability remained in both leachate and direct scaffold cultures. Genotoxicity assays showed low levels of DNA damage, with most cells displaying no detectable genotoxic effects, and mutagenicity tests revealed no significant differences compared to controls (p > 0.05). Overall, the results demonstrate that 3D BNC supports cell viability, multicellular organization, and genomic safety, highlighting its suitability as a biocompatible scaffold for in vitro 3D colon cancer models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Systems Biology Research Group, School of Health Sciences, Faculty of Medicine, Universidad Pontificia Bolivariana, Medellín, Colombia.
- New Materials Research Group, School of Engineering, Universidad Pontificia Bolivariana, Medellín, Colombia.
- NanoBioCel Group, Department of Pharmacy and Food Science, Faculty of Pharmacy, University of the Basque Country (UPV/ EHU), Vitoria-Gasteiz, Spain.
- Joint Research Laboratory (JRL) on Advanced Pharma Development, Centro de investigacón Lascaray ikergunea, A Joint Venture of TECNALIA and University of the Basque Country, Vitoria-Gasteiz, Spain.
- Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto De Salud Carlos III, Vitoria-Gasteiz, Spain.
- Bioaraba, NanoBioCel Research Group, Vitoria-Gasteiz, Spain.
ORCID-Profile: M Osorio
Förderung
- Ministerio de Ciencia, Tecnología e Innovación
- Projects Nanovehiculos
- Preclínico
- Basque Country Government
Zitieren
APA
Londoño, M., Castro, C., Cañas, A., Ruiz, S., Pedraz, J., & Osorio, M. (2026). Bacterial Nanocellulose as a Platform for Three‐Dimensional Colon Cancer Cultures: Physicochemical Characterization and Biocompatibility Evaluation. Macromolecular Bioscience. https://doi.org/10.1002/mabi.70272
Vancouver
Londoño M, Castro C, Cañas A, Ruiz S, Pedraz J, Osorio M. Bacterial Nanocellulose as a Platform for Three‐Dimensional Colon Cancer Cultures: Physicochemical Characterization and Biocompatibility Evaluation. Macromolecular Bioscience. 2026. doi:10.1002/mabi.70272
BibTeX
@article{Londoo2026,
author = {Londoño, M and Castro, C and Cañas, A and Ruiz, S and Pedraz, J and Osorio, M},
title = {Bacterial Nanocellulose as a Platform for Three‐Dimensional Colon Cancer Cultures: Physicochemical Characterization and Biocompatibility Evaluation},
journal = {Macromolecular Bioscience},
year = {2026},
doi = {10.1002/mabi.70272}
}
EUVIMED